Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

[1]  Y. Tao,et al.  Regulating tumor suppressor genes: post-translational modifications , 2020, Signal Transduction and Targeted Therapy.

[2]  S. Cairo,et al.  Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model , 2020, Nature Communications.

[3]  Jianjun Yu,et al.  Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer , 2020, EBioMedicine.

[4]  R. DiPaola,et al.  HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. , 2020, JAMA oncology.

[5]  S. Sakamoto.  Current status of circulating tumor cell androgen receptor splice variant-7 in metastatic castration-resistant prostate cancer. , 2019, Annals of translational medicine.

[6]  Natalie S. Fox,et al.  The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression , 2018, Cell.

[7]  C. Sander,et al.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets , 2018, Nature Genetics.

[8]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[9]  L. Macconaill,et al.  Frameshift events predict anti-PD-1/L1 response in head and neck cancer. , 2018, JCI insight.

[10]  E. Antonarakis,et al.  p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.

[11]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[12]  Zachary J. Heins,et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.

[13]  B. Trock,et al.  Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. , 2017, European urology.

[14]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[15]  F. Saad,et al.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.

[16]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[17]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[18]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[19]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[21]  Jennifer R. Rider,et al.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. , 2015, Journal of the National Cancer Institute.

[22]  K. Baggerly,et al.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.

[23]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[24]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[25]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[26]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[27]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[28]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[29]  Kyle J. Kiriluk,et al.  Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer , 2013, PloS one.

[30]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[31]  Paul G. Hynes,et al.  Characterizing the Contribution of Stem/Progenitor Cells to Tumorigenesis in the Pten−/−TP53−/− Prostate Cancer Model , 2010, Stem cells.

[32]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[33]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[34]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[35]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.